These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 36264573)

  • 21. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.
    Cheng Y; Fan Y; Zhao Y; Huang D; Li X; Zhang P; Kang M; Yang N; Zhong D; Wang Z; Yu Y; Zhang Y; Zhao J; Qin T; Chen C; Leaw S; Zheng W; Song Y;
    J Thorac Oncol; 2024 Jul; 19(7):1073-1085. PubMed ID: 38460751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
    Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
    Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and survival in patients with small cell lung cancer in Taiwan.
    Chiang CL; Hsieh WT; Tang CH; Sheu ML; Chen YM
    J Chin Med Assoc; 2021 Aug; 84(8):772-777. PubMed ID: 34183592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
    Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry.
    Hong JC; Boyer MJ; Spiegel DY; Williams CD; Tong BC; Shofer SL; Moravan MJ; Kelley MJ; Salama JK
    J Natl Compr Canc Netw; 2019 Feb; 17(2):127-139. PubMed ID: 30787126
    [No Abstract]   [Full Text] [Related]  

  • 27. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study.
    Karachiwala H; Tilley D; Abdel-Rahman O; Morris D
    Clin Respir J; 2021 Jan; 15(1):36-41. PubMed ID: 32803870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
    Agarwal M; Liu A; Langlais BT; Leventakos K; Yu NY; Almquist D; Manochakian R; Ernani V
    Clin Lung Cancer; 2023 Nov; 24(7):591-597. PubMed ID: 37365076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
    Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
    J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
    Seckl MJ; Ottensmeier CH; Cullen M; Schmid P; Ngai Y; Muthukumar D; Thompson J; Harden S; Middleton G; Fife KM; Crosse B; Taylor P; Nash S; Hackshaw A
    J Clin Oncol; 2017 May; 35(14):1506-1514. PubMed ID: 28240967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive-stage small cell lung cancer (ES-SCLC): Study protocol.
    Deng L; Shayan G; Jiang W; Bi N; Wang L
    Thorac Cancer; 2024 Apr; 15(11):938-943. PubMed ID: 38426233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.
    Chen H; Ma X; Liu J; Yang Y; He Y; Fang Y; Wang L; Fang J; Zhao J; Zhuo M
    Clin Transl Oncol; 2024 Jul; 26(7):1664-1673. PubMed ID: 38329610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
    Owonikoko TK; Dahlberg SE; Sica GL; Wagner LI; Wade JL; Srkalovic G; Lash BW; Leach JW; Leal TB; Aggarwal C; Ramalingam SS
    J Clin Oncol; 2019 Jan; 37(3):222-229. PubMed ID: 30523756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.